{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T05:38:13Z","timestamp":1768282693406,"version":"3.49.0"},"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T00:00:00Z","timestamp":1467072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006475","name":"Bergen Research Foundation","doi-asserted-by":"crossref","award":["does not have a number"],"award-info":[{"award-number":["does not have a number"]}],"id":[{"id":"10.13039\/501100006475","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Norwegian Cancer Society","award":["421828"],"award-info":[{"award-number":["421828"]}]},{"name":"The University of Bergen","award":["11754"],"award-info":[{"award-number":["11754"]}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["911809"],"award-info":[{"award-number":["911809"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["911789, 911884"],"award-info":[{"award-number":["911789, 911884"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Norwegian Cancer Society","award":["732200"],"award-info":[{"award-number":["732200"]}]},{"name":"The Norwegian Cancer Society","award":["421828"],"award-info":[{"award-number":["421828"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0158208","type":"journal-article","created":{"date-parts":[[2016,6,28]],"date-time":"2016-06-28T17:38:47Z","timestamp":1467135527000},"page":"e0158208","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":32,"title":["The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer"],"prefix":"10.1371","volume":"11","author":[{"given":"\u00d8ystein","family":"Helland","sequence":"first","affiliation":[]},{"given":"Mihaela","family":"Popa","sequence":"additional","affiliation":[]},{"given":"Katharina","family":"Bischof","sequence":"additional","affiliation":[]},{"given":"Bj\u00f8rn Tore","family":"Gjertsen","sequence":"additional","affiliation":[]},{"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[]},{"given":"Line","family":"Bj\u00f8rge","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,6,28]]},"reference":[{"issue":"1","key":"ref1","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"R Siegel","year":"2014","journal-title":"CA: a cancer journal for clinicians"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2002.31589","article-title":"Surgical management of ovarian cancer","volume":"29","author":"DG Mutch","year":"2002","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"ref3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1023\/A:1008355317514","article-title":"First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer\u2014a new standard of care?","volume":"10","author":"A du Bois","year":"1999","journal-title":"Ann Oncol"},{"issue":"17","key":"ref4","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"RF Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"ref5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"TA Yap","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2011.0008","article-title":"Epithelial ovarian cancer","volume":"9","author":"RJ Morgan Jr.","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"issue":"26","key":"ref7","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"TJ Perren","year":"2011","journal-title":"The New England journal of medicine"},{"issue":"15","key":"ref8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"J Ledermann","year":"2012","journal-title":"The New England journal of medicine"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"DK Armstrong","year":"2006","journal-title":"The New England journal of medicine"},{"issue":"13","key":"ref10","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","article-title":"Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial","volume":"21","author":"M Markman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.tjog.2012.04.002","article-title":"Metronomic therapy for gynecologic cancers","volume":"51","author":"WH Su","year":"2012","journal-title":"Taiwanese journal of obstetrics & gynecology"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.canlet.2009.02.019","article-title":"Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges","volume":"280","author":"P Atadja","year":"2009","journal-title":"Cancer letters"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.cell.2007.01.029","article-title":"The epigenomics of cancer","volume":"128","author":"PA Jones","year":"2007","journal-title":"Cell"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"164","DOI":"10.4161\/epi.3.3.6253","article-title":"A work in progress: the clinical development of histone deacetylase inhibitors","volume":"3","author":"S Marsoni","year":"2008","journal-title":"Epigenetics: official journal of the DNA Methylation Society"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrg1748","article-title":"The epigenetic progenitor origin of human cancer","volume":"7","author":"AP Feinberg","year":"2006","journal-title":"Nature reviews Genetics"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fonc.2014.00071","article-title":"Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?","volume":"4","author":"HT Nguyen","year":"2014","journal-title":"Frontiers in oncology"},{"issue":"4","key":"ref17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"MS Kim","year":"2001","journal-title":"Nat Med"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3802\/jgo.2008.19.3.185","article-title":"Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues","volume":"19","author":"KL Jin","year":"2008","journal-title":"Journal of gynecologic oncology"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/1078-0432.CCR-05-1132","article-title":"Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589","volume":"12","author":"DZ Qian","year":"2006","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","article-title":"Anticancer activities of histone deacetylase inhibitors","volume":"5","author":"JE Bolden","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bcp.2007.04.007","article-title":"HDAC inhibitors: clinical update and mechanism-based potential","volume":"74","author":"KB Glaser","year":"2007","journal-title":"Biochemical pharmacology"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"BS Mann","year":"2007","journal-title":"The oncologist"},{"issue":"22","key":"ref23","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"RL Piekarz","year":"2011","journal-title":"Blood"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40265-015-0388-8","article-title":"Panobinostat: first global approval","volume":"75","author":"KP Garnock-Jones","year":"2015","journal-title":"Drugs"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nrd772","article-title":"Histone-deacetylase inhibitors: novel drugs for the treatment of cancer","volume":"1","author":"RW Johnstone","year":"2002","journal-title":"Nature reviews Drug discovery"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2012.08.035","article-title":"Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K\/Akt pathway in vitro","volume":"329","author":"H Chao","year":"2013","journal-title":"Cancer letters"},{"issue":"3","key":"ref27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.09.016","article-title":"Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer","volume":"127","author":"AJ Wilson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"8","key":"ref28","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.7314\/APJCP.2012.13.8.3977","article-title":"Effects of valproic acid on proliferation, apoptosis, angiogenesis and metastasis of ovarian cancer in vitro and in vivo","volume":"13","author":"Z Shan","year":"2012","journal-title":"Asian Pacific journal of cancer prevention: APJCP"},{"issue":"12","key":"ref29","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1002\/cncr.20709","article-title":"Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis","volume":"101","author":"N Takai","year":"2004","journal-title":"Cancer"},{"issue":"8","key":"ref30","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","article-title":"Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies","volume":"5","author":"X Qian","year":"2006","journal-title":"Molecular cancer therapeutics"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2006.09.011","article-title":"In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer","volume":"104","author":"AL Cooper","year":"2007","journal-title":"Gynecologic oncology"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.ymthe.2004.08.013","article-title":"Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer","volume":"10","author":"TJ Shaw","year":"2004","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"e89527","DOI":"10.1371\/journal.pone.0089527","article-title":"First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma","volume":"9","author":"O Helland","year":"2014","journal-title":"PloS one"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s10637-010-9467-6","article-title":"The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines","volume":"29","author":"DR Budman","year":"2011","journal-title":"Investigational new drugs"},{"issue":"Pt 12","key":"ref35","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1242\/jcs.107.12.3363","article-title":"Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line","volume":"107","author":"BT Gjertsen","year":"1994","journal-title":"Journal of cell science"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrd1609","article-title":"Multicomponent therapeutics for networked systems","volume":"4","author":"CT Keith","year":"2005","journal-title":"Nature reviews Drug discovery"},{"issue":"9","key":"ref37","first-page":"1025","article-title":"Cytoreductive surgery in the management of ovarian cancer","volume":"22","author":"PE Schwartz","year":"2008","journal-title":"Oncology"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s10637-013-9930-2","article-title":"A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors","volume":"31","author":"S Sharma","year":"2013","journal-title":"Investigational new drugs"},{"issue":"Suppl 1","key":"ref39","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10637-010-9596-y","article-title":"Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect","volume":"28","author":"M Dickinson","year":"2010","journal-title":"Investigational new drugs"},{"issue":"5","key":"ref40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2217\/fon.09.36","article-title":"Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors","volume":"5","author":"HM Prince","year":"2009","journal-title":"Future oncology"},{"issue":"3","key":"ref41","doi-asserted-by":"crossref","first-page":"R79","DOI":"10.1186\/bcr3192","article-title":"Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat","volume":"14","author":"CR Tate","year":"2012","journal-title":"Breast cancer research: BCR"},{"key":"ref42","article-title":"Growth inhibition of pancreatic cancer cells by Histone Deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo","author":"W Chien","year":"2013","journal-title":"Molecular carcinogenesis"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s10637-012-9914-7","article-title":"Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer","volume":"31","author":"PM Wilson","year":"2013","journal-title":"Investigational new drugs"},{"issue":"17","key":"ref44","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"A du Bois","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"Suppl 5","key":"ref45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","article-title":"Management of treatment-related toxicity in advanced ovarian cancer","volume":"7","author":"CJ Dunton","year":"2002","journal-title":"The oncologist"},{"issue":"3","key":"ref46","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/annonc\/mdr321","article-title":"Trabectedin plus pegylated liposomal doxorubicin in the treatment of patients with partially platinum-sensitive ovarian cancer: current evidence and future perspectives","volume":"23","author":"J Sehouli","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 10","key":"ref47","doi-asserted-by":"crossref","first-page":"x313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology","volume":"23","author":"M Joerger","year":"2012","journal-title":"Ann Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.2147\/OTT.S30773","article-title":"Profile of panobinostat and its potential for treatment in solid tumors: an update","volume":"6","author":"M Anne","year":"2013","journal-title":"OncoTargets and therapy"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1517\/13543784.2013.815165","article-title":"Panobinostat in lymphoid and myeloid malignancies","volume":"22","author":"A Khot","year":"2013","journal-title":"Expert opinion on investigational drugs"},{"issue":"12 Suppl","key":"ref50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/fon.13.206","article-title":"Optimizing treatment of the partially platinum-sensitive ovarian cancer patient","volume":"9","author":"N Colombo","year":"2013","journal-title":"Future oncology"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1634\/theoncologist.4-2-87","article-title":"Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy","volume":"4","author":"MA Bookman","year":"1999","journal-title":"The oncologist"},{"issue":"2","key":"ref52","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6\u201312 months post platinum-based chemotherapy","volume":"64","author":"N Colombo","year":"2007","journal-title":"Critical reviews in oncology\/hematology"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ygyno.2004.03.047","article-title":"The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model","volume":"94","author":"NS Horowitz","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"GC Stuart","year":"2011","journal-title":"International journal of gynecological cancer: official journal of the International Gynecological Cancer Society"},{"issue":"3","key":"ref55","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ctrv.2013.08.001","article-title":"Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: focus on trabectedin","volume":"40","author":"A Poveda","year":"2014","journal-title":"Cancer treatment reviews"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"S Domcke","year":"2013","journal-title":"Nature communications"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.coph.2010.06.012","article-title":"The challenge of selecting the 'right' in vivo oncology pharmacology model","volume":"10","author":"B Firestone","year":"2010","journal-title":"Current opinion in pharmacology"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"458431","DOI":"10.1155\/2010\/458431","article-title":"Histone deacetylase inhibitor therapy in epithelial ovarian cancer","volume":"2010","author":"N Takai","year":"2010","journal-title":"Journal of oncology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0158208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T09:06:00Z","timestamp":1656752760000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0158208"}},"subtitle":[],"editor":[{"given":"Ramesh","family":"Balusu","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,6,28]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0158208","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,28]]}}}